Past Issues

• 8

  Artificial Intelligence and the Healthcare Industry

  Kelly H. Zou, PhD., PStat®, FASA, Head of Global Medical Analytics and Real World Evidence, Viatris

• 12

  How Technology Enhances the Effectiveness of Compliance Programs

  Patrik Florencio, Svp and Chief Compliance & Risk Officer, Amicus Therapeutics

• 19

  Challenges And Opportunities For AI In Drug Discovery

  Robert J. Prill, and Yong Yue, Director, Data Science and AI, Computational Biology and Data Sciences, and Senior Director, Computational Biology and Data Sciences, Ferring Research Institute, Inc.

• 22

  Advanced Therapies for Patients Suffering from PAH

  Shola Oyewole, CIO, United Therapeutics Corporation [NASDAQ:UTHR]

• 24

  Setting a Culture for Digital Transformation in the Biopharmaceutical Industry

  Ross Kenyon, P.E. , Associate Director, Modeling, Simulation and Analysis, Regeneron Pharmaceuticals

• 26

  Analytical Considerations for Combination Products

  Jennifer L. Riter, Sr. Director, Business and Technical Operations, Services and Solutions, West Pharmaceutical Services, Inc.

• 28

  Three C’s to Enable Continuous Development and Manufacturing for Small Molecule Active Pharmaceutical Ingredient

  Nick Thomson, Senior Director, Chemical Research and Development, Pfizer Inc

• 30

  From ideation to portfolio program: Innovation vs validation in early drug discovery

  Carlos Pedraza, PhD., Director of CNS Biology, Alkermes